These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 24706190)

  • 1. Suitable drug combination with bortezomib for multiple myeloma under stroma-free conditions and in contact with fibronectin or bone marrow stromal cells.
    Kikuchi J; Koyama D; Mukai HY; Furukawa Y
    Int J Hematol; 2014 Jun; 99(6):726-36. PubMed ID: 24706190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia.
    Yanamandra N; Colaco NM; Parquet NA; Buzzeo RW; Boulware D; Wright G; Perez LE; Dalton WS; Beaupre DM
    Clin Cancer Res; 2006 Jan; 12(2):591-9. PubMed ID: 16428505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The mechanisms of drug resistance via the interaction of myeloma cells with stromal cells].
    Kikuchi J; Furukawa Y
    Nihon Rinsho; 2015 Jan; 73(1):57-61. PubMed ID: 25626305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.
    Azab AK; Runnels JM; Pitsillides C; Moreau AS; Azab F; Leleu X; Jia X; Wright R; Ospina B; Carlson AL; Alt C; Burwick N; Roccaro AM; Ngo HT; Farag M; Melhem MR; Sacco A; Munshi NC; Hideshima T; Rollins BJ; Anderson KC; Kung AL; Lin CP; Ghobrial IM
    Blood; 2009 Apr; 113(18):4341-51. PubMed ID: 19139079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
    Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC
    Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibroblast activation protein protects bortezomib-induced apoptosis in multiple myeloma cells through β-catenin signaling pathway.
    Zi FM; He JS; Li Y; Wu C; Wu WJ; Yang Y; Wang LJ; He DH; Yang L; Zhao Y; Zheng GF; Han XY; Huang H; Yi Q; Cai Z
    Cancer Biol Ther; 2014 Oct; 15(10):1413-22. PubMed ID: 25046247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro cytotoxicity of the novel antimyeloma agents perifosine, bortezomib and lenalidomide against different cell lines.
    Schmidt-Hieber M; Dabrowski R; Weimann A; Aicher B; Lohneis P; Busse A; Thiel E; Blau IW
    Invest New Drugs; 2012 Apr; 30(2):480-9. PubMed ID: 21080211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bortezomib restores stroma-mediated APO2L/TRAIL apoptosis resistance in multiple myeloma.
    Perez LE; Parquet N; Meads M; Anasetti C; Dalton W
    Eur J Haematol; 2010 Mar; 84(3):212-22. PubMed ID: 19922463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells.
    Chauhan D; Li G; Podar K; Hideshima T; Mitsiades C; Schlossman R; Munshi N; Richardson P; Cotter FE; Anderson KC
    Blood; 2004 Oct; 104(8):2458-66. PubMed ID: 15217830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression.
    Hao M; Zhang L; An G; Meng H; Han Y; Xie Z; Xu Y; Li C; Yu Z; Chang H; Qiu L
    Leuk Lymphoma; 2011 Sep; 52(9):1787-94. PubMed ID: 21534877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myeloma cell adhesion to bone marrow stromal cells confers drug resistance by microRNA-21 up-regulation.
    Wang X; Li C; Ju S; Wang Y; Wang H; Zhong R
    Leuk Lymphoma; 2011 Oct; 52(10):1991-8. PubMed ID: 21718132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide.
    Abeltino M; Bonomini S; Bolzoni M; Storti P; Colla S; Todoerti K; Agnelli L; Neri A; Rizzoli V; Giuliani N
    Exp Hematol; 2011 Jan; 39(1):55-65. PubMed ID: 20977926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vorinostat enhances the antimyeloma effects of melphalan and bortezomib.
    Campbell RA; Sanchez E; Steinberg J; Shalitin D; Li ZW; Chen H; Berenson JR
    Eur J Haematol; 2010 Mar; 84(3):201-11. PubMed ID: 19929977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
    Voorhees PM; Chen Q; Kuhn DJ; Small GW; Hunsucker SA; Strader JS; Corringham RE; Zaki MH; Nemeth JA; Orlowski RZ
    Clin Cancer Res; 2007 Nov; 13(21):6469-78. PubMed ID: 17975159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias.
    O'Connor R; Ooi MG; Meiller J; Jakubikova J; Klippel S; Delmore J; Richardson P; Anderson K; Clynes M; Mitsiades CS; O'Gorman P
    Cancer Chemother Pharmacol; 2013 May; 71(5):1357-68. PubMed ID: 23589314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Galectin-3C inhibits tumor growth and increases the anticancer activity of bortezomib in a murine model of human multiple myeloma.
    Mirandola L; Yu Y; Chui K; Jenkins MR; Cobos E; John CM; Chiriva-Internati M
    PLoS One; 2011; 6(7):e21811. PubMed ID: 21765917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells.
    Kiziltepe T; Hideshima T; Catley L; Raje N; Yasui H; Shiraishi N; Okawa Y; Ikeda H; Vallet S; Pozzi S; Ishitsuka K; Ocio EM; Chauhan D; Anderson KC
    Mol Cancer Ther; 2007 Jun; 6(6):1718-27. PubMed ID: 17575103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro migratory aberrancies of mesenchymal stem cells derived from multiple myeloma patients only partially modulated by bortezomib.
    Xu X; Yang J; Tang Y; Li J; Zhu Y; Lu H; Fei X
    Int J Clin Exp Pathol; 2014; 7(10):6705-15. PubMed ID: 25400750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alkylating agents induce activation of NFkappaB in multiple myeloma cells.
    Baumann P; Mandl-Weber S; Oduncu F; Schmidmaier R
    Leuk Res; 2008 Jul; 32(7):1144-7. PubMed ID: 18083229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toll-like receptor (TLR)-1/2 triggering of multiple myeloma cells modulates their adhesion to bone marrow stromal cells and enhances bortezomib-induced apoptosis.
    Abdi J; Mutis T; Garssen J; Redegeld FA
    PLoS One; 2014; 9(5):e96608. PubMed ID: 24794258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.